Correlation Between Hansa Biopharma and CellaVision

Can any of the company-specific risk be diversified away by investing in both Hansa Biopharma and CellaVision at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hansa Biopharma and CellaVision into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hansa Biopharma AB and CellaVision AB, you can compare the effects of market volatilities on Hansa Biopharma and CellaVision and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hansa Biopharma with a short position of CellaVision. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hansa Biopharma and CellaVision.

Diversification Opportunities for Hansa Biopharma and CellaVision

0.68

Correlation Coefficient

Hansa Biopharma  CellaVision

Poor diversification

The 3 months correlation between Hansa and CellaVision is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Hansa Biopharma AB and CellaVision AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CellaVision AB and Hansa Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hansa Biopharma AB are associated (or correlated) with CellaVision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CellaVision AB has no effect on the direction of Hansa Biopharma i.e., Hansa Biopharma and CellaVision go up and down completely randomly.

Pair Corralation between Hansa Biopharma and CellaVision

Assuming the 90 days trading horizon Hansa Biopharma AB is expected to under-perform the CellaVision. In addition to that, Hansa Biopharma is 1.44 times more volatile than CellaVision AB. It trades about -0.2 of its total potential returns per unit of risk. CellaVision AB is currently generating about -0.1 per unit of volatility. If you would invest  26,600  in CellaVision AB on August 31, 2024 and sell it today you would lose (4,200) from holding CellaVision AB or give up 15.79% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Hansa Biopharma AB  vs.  CellaVision AB

Hansa Biopharma AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hansa Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

CellaVision AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CellaVision AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Hansa Biopharma and CellaVision

The main advantage of trading using opposite Hansa Biopharma and CellaVision positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hansa Biopharma position performs unexpectedly, CellaVision can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CellaVision will offset losses from the drop in CellaVision's long position.

The idea behind Hansa Biopharma AB and CellaVision AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.